CAR T-cell therapy for T-cell lymphoma shows promise in phase I study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital have developed a chimeric antigen receptor (CAR) T-cell therapy targeting T-cell lymphoma, an aggressive and difficult to treat cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login